<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134692</url>
  </required_header>
  <id_info>
    <org_study_id>NG002</org_study_id>
    <nct_id>NCT01134692</nct_id>
  </id_info>
  <brief_title>Probiotics for Portal Hypertension</brief_title>
  <official_title>COMPARATIVE STUDY OF NORFLOXACIN AND PROBIOTICS ON PORTAL PRESSURE IN PATIENTS WITH CIRRHOSIS AND LARGE VARICES WHO HAVE NEVER BLED IN THE PAST</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Govind Ballabh Pant Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Govind Ballabh Pant Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic peripheral and splanchnic vasodilatation are the hallmark hemodynamic abnormality in&#xD;
      cirrhosis and contribute to the pathogenesis of portal hypertension.&#xD;
&#xD;
      Alterations in intestinal motility and bacterial overgrowth in gut may predispose to the&#xD;
      development of bacteraemia and endotoxaemia in cirrhotic patients which play a role in the&#xD;
      hyperdynamic circulatory syndrome of cirrhosis. Probiotic therapy is aimed at changing the&#xD;
      make-up of the indigenous microflora by administering specific strains of non-pathogenic and&#xD;
      potentially beneficial microflora. In this study, the investigators hypothesize that a&#xD;
      modification in the composition of the endogenous digestive microflora by oral&#xD;
      bacteriotherapy with high potency probiotic preparations could be a safe way to regulate the&#xD;
      portal pressure.&#xD;
&#xD;
      As there is a relative paucity in effective pharmacological treatment for portal&#xD;
      hypertension, these novel and innovative therapy might provide important alternative or&#xD;
      adjunct therapy to beta blockers in the clinical management of patients with portal&#xD;
      hypertension.&#xD;
&#xD;
      Aims and objectives&#xD;
&#xD;
      To study in patients with cirrhosis and large varices whether probiotics and/or norfloxacin&#xD;
      given for 2 months :&#xD;
&#xD;
        1. achieve a reduction in HVPG&#xD;
&#xD;
        2. alter the endotoxin and cytokine levels, and improve systemic inflammatory responses&#xD;
&#xD;
        3. well tolerated.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
      Consecutive patients of cirrhosis with portal hypertension who fulfill the following&#xD;
      criteria:&#xD;
&#xD;
        1. Diagnosed cases of cirrhosis (by clinical, biochemical and radiological criteria with or&#xD;
           without liver biopsy)&#xD;
&#xD;
        2. No history of upper GI bleeding in the past&#xD;
&#xD;
        3. Endoscopically documented large esophageal varices&#xD;
&#xD;
      Exclusion criteria&#xD;
&#xD;
        1. history of gastrointestinal bleeding&#xD;
&#xD;
        2. patients who have received beta blockers for portal hypertension in the past 6 weeks.&#xD;
&#xD;
        3. hepatic encephalopathy&#xD;
&#xD;
        4. ongoing bacterial infection,&#xD;
&#xD;
        5. Spontaneous bacterial peritonitis&#xD;
&#xD;
        6. active alcoholism or illicit drug abuse&#xD;
&#xD;
        7. alcoholic hepatitis&#xD;
&#xD;
        8. Treatment with antibiotics in the preceding 2 weeks.&#xD;
&#xD;
        9. presence of hepatocellular carcinoma,&#xD;
&#xD;
       10. portal vein thrombosis&#xD;
&#xD;
       11. serum creatinine&gt;1.5 mg/dL,&#xD;
&#xD;
       12. treatment with vasoactive drugs in the past 6 weeks,&#xD;
&#xD;
       13. history of arterial hypertension, congestive heart failure or arterial occlusive&#xD;
           disease, and&#xD;
&#xD;
       14. Refusal to participate.&#xD;
&#xD;
       15. Active smokers.&#xD;
&#xD;
      Study plan:&#xD;
&#xD;
      Ethical approval will be obtained prior to study initiation. Patients presenting to&#xD;
      Department of Gastroenterology, GB Pant Hospital will be recruited in the study. Patients&#xD;
      will be evaluated regarding the eligibility for the study. After being found eligible for the&#xD;
      study, if the patient agrees to participate in the study, a signed informed consent will be&#xD;
      obtained. Baseline HVPG will be measured in all patients and then they will be randomized&#xD;
      into 3 groups:.&#xD;
&#xD;
        1. Group 1: Beta blockers + placebo&#xD;
&#xD;
        2. Group 2: Beta blockers + Norfloxacin (400mg BD)&#xD;
&#xD;
        3. Group 3: Beta blockers + probiotics. (one sachet of VSL#3 BD)&#xD;
&#xD;
      30 patients will be enrolled into each group. The treatment will be continued for 2 months.&#xD;
&#xD;
      The study design is a randomized double-blinded placebo controlled trial.&#xD;
&#xD;
      Once patients have been enrolled, they will undergo baseline investigations. Blood will be&#xD;
      drawn from both peripheral and hepatic veins and sent for routine parameters,&#xD;
      pro-inflammatory cytokines (IL-1b, IL-6, IL-10, TNF-α, endotoxins, NO2 and NO3 levels, PRA,&#xD;
      BNP). Samples will be stored at -70 ºC. Baseline vitals will be recorded.&#xD;
&#xD;
      Patients will be called at the end of 1 month for assessment of compliance and then at the&#xD;
      end of the study (2 months) to repeat the HVPG and the same parameters as at the time of&#xD;
      enrollment&#xD;
&#xD;
      End Points:&#xD;
&#xD;
        1. Primary&#xD;
&#xD;
           a. Change in HVPG levels as compared with baseline, to define responder (≥20% reduction&#xD;
           in HVPG or ≤ 12 mm Hg).&#xD;
&#xD;
        2. Secondary&#xD;
&#xD;
             1. Change in digestive flora&#xD;
&#xD;
             2. Reduction in serum and hepatic endotoxin and cytokine levels&#xD;
&#xD;
             3. Assessment of improvement in the renal parameters and Systemic inflammatory&#xD;
                response syndrome&#xD;
&#xD;
             4. Improvement in the markers of oxidative injury&#xD;
&#xD;
             5. Adverse effects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HVPG levels as compared with baseline, to define responder (≥20% reduction in HVPG or ≤ 12 mm Hg).</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of improvement in the renal parameters and Systemic inflammatory response syndrome</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <condition>Cirrhosis</condition>
  <condition>Varices, Esophageal</condition>
  <arm_group>
    <arm_group_label>Propranolol + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol + Norfloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol + Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VSL#3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol, Norfloxacin, VSL#3</intervention_name>
    <description>Propranolol: as per heart rate titration Norfloxacin: 400mg BD</description>
    <arm_group_label>Propranolol + Norfloxacin</arm_group_label>
    <arm_group_label>Propranolol + Placebo</arm_group_label>
    <arm_group_label>Propranolol + Probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Consecutive patients of cirrhosis with portal hypertension who fulfill the following&#xD;
        criteria:&#xD;
&#xD;
          1. Diagnosed cases of cirrhosis (by clinical, biochemical and radiological criteria with&#xD;
             or without liver biopsy)&#xD;
&#xD;
          2. No history of upper GI bleeding in the past&#xD;
&#xD;
          3. Endoscopically documented large esophageal varices&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. history of gastrointestinal bleeding&#xD;
&#xD;
          2. patients who have received beta blockers for portal hypertension in the past 6 weeks.&#xD;
&#xD;
          3. hepatic encephalopathy&#xD;
&#xD;
          4. ongoing bacterial infection,&#xD;
&#xD;
          5. Spontaneous bacterial peritonitis&#xD;
&#xD;
          6. active alcoholism or illicit drug abuse&#xD;
&#xD;
          7. alcoholic hepatitis&#xD;
&#xD;
          8. Treatment with antibiotics in the preceding 2 weeks.&#xD;
&#xD;
          9. presence of hepatocellular carcinoma,&#xD;
&#xD;
         10. portal vein thrombosis&#xD;
&#xD;
         11. serum creatinine&gt;1.5 mg/dL,&#xD;
&#xD;
         12. treatment with vasoactive drugs in the past 6 weeks,&#xD;
&#xD;
         13. history of arterial hypertension, congestive heart failure or arterial occlusive&#xD;
             disease, and&#xD;
&#xD;
         14. Refusal to participate.&#xD;
&#xD;
         15. Active smokers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nitin Gupta, MD</last_name>
    <phone>+919718599209</phone>
    <email>drnitingupta_id@rediffmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GB Pant hospital</name>
      <address>
        <city>Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nitin Gupta, MD</last_name>
      <phone>+919718599209</phone>
      <email>drnitingupta_id@rediffmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>June 1, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <last_update_submitted>June 1, 2010</last_update_submitted>
  <last_update_submitted_qc>June 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nitin Gupta</name_title>
    <organization>G.B. Pant Hospital, Delhi</organization>
  </responsible_party>
  <keyword>Patients with cirrhosis who have large esophageal varices with No history of upper GI bleeding in the past</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norfloxacin</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

